Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.

about

Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.

Item

http://www.wikidata.org/entity/Q48316634

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Variability of platelet respon ...... taneous coronary intervention.

@en

Variability of platelet respon ...... taneous coronary intervention.

@nl

type

Item

label

Variability of platelet respon ...... taneous coronary intervention.

@en

Variability of platelet respon ...... taneous coronary intervention.

@nl

prefLabel

Variability of platelet respon ...... taneous coronary intervention.

@en

Variability of platelet respon ...... taneous coronary intervention.

@nl

P1476

Variability of platelet respon ...... utaneous coronary intervention

@en

P2093

Jarosław Gorący

http://www.w3.org/2001/XMLSchema#string

Maria Jastrzębska

http://www.w3.org/2001/XMLSchema#string

Radosław Kiedrowicz

http://www.w3.org/2001/XMLSchema#string

Zdzisława Kornacewicz-Jach

http://www.w3.org/2001/XMLSchema#string

P2860

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.

Antiplatelet drug interactions with proton pump inhibitors

ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

Additive effect of anemia and renal impairment on long-term outcome after percutaneous coronary intervention

Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.

P2888

s00228-017-2271-x

P304

1085-1094

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-017-2271-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Krzysztof Safranow

Barbara Gawronska-Szklarz

Szymon Olędzki

P577

2017-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28589365

http://www.w3.org/2001/XMLSchema#string

P921

clopidogrel